Jeyaraman Madhan, Jeyaraman Naveen, Ramasubramanian Swaminathan, Balaji Sangeetha, Muthu Sathish
Department of Orthopedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India.
Department of Research Methods, Orthopedic Research Group, Coimbatore 641045, Tamil Nadu, India.
World J Orthop. 2024 Oct 18;15(10):908-917. doi: 10.5312/wjo.v15.i10.908.
The field of orthopedic and regenerative medicine is rapidly evolving with the increasing utilization of orthobiologic. These biologically derived therapies, including platelet-rich plasma, mesenchymal stem cells, bone marrow aspirate concentrate, stromal vascular fraction (SVF), and autologous chondrocyte implantation, are gaining traction for their potential to enhance the body's natural healing processes. They offer a promising alternative to traditional surgical interventions for musculoskeletal injuries and degenerative conditions. Current evidence suggests significant benefits of orthobiologics in treating conditions like osteoarthritis, tendon injuries, and spinal disorders, yet inconsistencies in treatment protocols and outcomes persist. The global market for orthobiologics is projected to grow substantially, driven by advancements in biologic therapies such as adipose-derived stem cells and SVF, and the demand for minimally invasive treatments. Despite their promise, regulatory and ethical challenges, as well as the need for high-quality, standardized research, remain significant obstacles. Future directions in the field include advancements in delivery systems, personalized medicine approaches, and the exploration of novel sources like induced pluripotent stem cells, aiming for more targeted and effective treatments. Collaborative efforts are crucial to overcoming these challenges and ensuring the safe and effective application of orthobiologics in clinical practice.
随着骨科生物制剂应用的不断增加，骨科和再生医学领域正在迅速发展。这些生物衍生疗法，包括富血小板血浆、间充质干细胞、骨髓抽吸浓缩物、基质血管成分（SVF）和自体软骨细胞植入，因其增强人体自然愈合过程的潜力而越来越受到关注。它们为肌肉骨骼损伤和退行性疾病的传统手术干预提供了一种有前景的替代方案。目前的证据表明，骨科生物制剂在治疗骨关节炎、肌腱损伤和脊柱疾病等病症方面具有显著益处，但治疗方案和结果仍存在不一致之处。受脂肪来源干细胞和SVF等生物疗法的进步以及对微创治疗的需求推动，全球骨科生物制剂市场预计将大幅增长。尽管它们前景广阔，但监管和伦理挑战以及对高质量、标准化研究的需求仍然是重大障碍。该领域的未来方向包括递送系统的进步、个性化医疗方法以及对诱导多能干细胞等新来源的探索，旨在实现更有针对性和更有效的治疗。合作努力对于克服这些挑战并确保骨科生物制剂在临床实践中的安全有效应用至关重要。
